Literature DB >> 32739007

Experimental studies of mitochondrial and lysosomal function in in vitro and in vivo models relevant to Parkinson's disease genetic risk.

Ria Thomas1, Penelope J Hallett2, Ole Isacson3.   

Abstract

Several studies have identified the involvement of mitochondrial and lysosomal dysfunction in Parkinson's disease (PD) pathology. In this review we discuss recent work that has identified deficits in mitophagy, mitochondrial network formation, increased sensitivity to mitochondrial stressors and alterations in proteins regulating mitochondrial fission and fusion associated with patient-derived fibroblasts harboring mutations in LRRK2 gene and from sporadic PD patient cells. We further focus on alterations of lysosomal enzymes, in particular glucocerebrosidase activity, and resultant lipid dyshomeostasis in PD and aging, in human tissue and in vivo rodent models. Future studies aimed at understanding the convergence of mitochondrial and lysosomal pathways will be of essence for the identification of unique cellular defects in PD and for the development of new treatments.
© 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  GBA; LRRK2; Lysosomal dysfunction; Mitochondrial dysfunction; Parkinson's disease; Patient fibroblasts

Year:  2020        PMID: 32739007     DOI: 10.1016/bs.irn.2020.02.004

Source DB:  PubMed          Journal:  Int Rev Neurobiol        ISSN: 0074-7742            Impact factor:   3.230


  3 in total

Review 1.  Human-Induced Pluripotent Stem Cell-Based Models for Studying Sex-Specific Differences in Neurodegenerative Diseases.

Authors:  Erkan Kiris
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 3.650

2.  Fibroblasts from idiopathic Parkinson's disease exhibit deficiency of lysosomal glucocerebrosidase activity associated with reduced levels of the trafficking receptor LIMP2.

Authors:  Ria Thomas; Elizabeth B Moloney; Zachary K Macbain; Penelope J Hallett; Ole Isacson
Journal:  Mol Brain       Date:  2021-01-19       Impact factor: 4.041

Review 3.  Approaches to Disease Modification for Parkinson's Disease: Clinical Trials and Lessons Learned.

Authors:  Albert Y Hung; Michael A Schwarzschild
Journal:  Neurotherapeutics       Date:  2020-11-17       Impact factor: 7.620

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.